436095-13-5

Upstream product

• 851721-95-4 1-(2,3-dimethyl-phenyl)-1H-tetrazole-5-thiol 
• 79-11-8 chloroacetic acid 
• 1200439-85-5 [1-(2,3-dimethyl-phenyl)-1H-tetrazol-5-ylsulfanyl]-acetic acid ethyl ester 
• 1539-20-4 1-isothiocyanato-2,3-dimethylbenzene 

Downstream Products

• 1200438-27-2 2-[1-(2,3-dimethyl-phenyl)-1H-tetrazol-5-ylsulfanyl]-N-[2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-acetamide 
• 1200438-28-3 2-[1-(2,3-dimethyl-phenyl)-1H-tetrazol-5-ylsulfanyl]-N-[2-(4-methoxy-3-methyl-benzyl)-2H-pyrazol-3-yl]-acetamide 
• 1200439-62-8 N-[2-(3,4-dichloro-phenyl)-2H-pyrazol-3-yl]-2-[1-(2,3-dimethyl-phenyl)-1H-tetrazol-5-ylsulfanyl]-acetamide 

Relevant academic research and scientific papers

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant

A series of aryltetrazolylacetanilides was synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors on wild-type virus and on the clinically relevant K103N mutant strain. Extensive SAR investigation led to potent compounds, with nanomolar activity on K103N, and orally bioavailable in rats.